此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Intravenous LIGNOcaine for the POstoperative Sore Throat (LIGNO-POST)

2026年11月9日 更新者:Ka Ting Ng、University of Malaya

Intravenous LIGNOcaine for the POstoperative Sore Throat: A Double-blinded Randomised Placebo-controlled Trial (LIGNO-POST Trial)

Patients often encounter unpleasant sore throat after surgery when wake up from general anaesthesia and pulling off breathing tube. Lignocaine is a medication used in anaesthesia for the properties of analgesia and anti-inflammation. Other studies suggested that lignocaine spray/ gel can reduce the postoperative sore throat after extubation in patients undergoing surgery. However, it can reduce the gag reflex, resulting in higher risk of aspiration after surgery. Therefore, this randomized, double-blind, placebo-controlled trial is designed to determine whether giving intravenous lignocaine toward the end of the surgery before extubation can reduce postoperative sore throat and discomfort after surgery. It is hypothesized that intravenous lignocaine can reduce postoperative sore throat in patients undergoing general anaesthesia.

研究概览

详细说明

Postoperative sore throat (POST) is a common and discomfort adverse event following general anaesthesia with orotracheal intubation, with reported incidences ranging from 30% to 70%. It is characterized by pain or discomfort at the larynx or pharynx during postoperative period in the recovery area, which can affect the overall perioperative experience and patient satisfaction. The pathophysiology of POST is believed due to mechanical trauma to the pharyngeal and laryngeal mucosa during intubation, cuff-related pressure injury, and airway inflammation that cause postoperative throat symptoms. Several non-pharmacological and pharmacological measures such as lozenges, gargles, lignocaine spray and steroid injection have been experimented with mixed findings.

Lignocaine is a local anaesthetic agent, which has the properties of analgesia and anti-inflammatory effect via the blockade of sodium channel receptor. Lignocaine spray at the throat is believed to reduce the severity of POST at various concentration (2%, 5% and 10%). However, studies reported that some of the additives agents (methanol, ethanol) in the lignocaine spray have irritating side effects to damage tracheal mucosa, negating the effect of topical lignocaine on the incidence of POST. In addition, topicalized lignocaine reduces the gag reflex if given too late before extubation, resulting in higher risk of aspiration in the recovery area.

In a routine general anaesthesia, intravenous dexamethasone is administered as an analgesic adjunct and anti-inflammatory to minimize airway edema. Administering intravenous lignocaine prior to extubation is believed to provide analgesic effect to reduce incidence of POST and postoperative cough after general anaesthesia. However, the evidence regarding its effect on POST remains limited and inconsistent, particularly when administered near the time of emergence from general anaesthesia.

Therefore, this randomized, double-blind, placebo-controlled trial is aimed to examine the use of intravenous lignocaine prior to extubation in the reduction of POST in surgical patients undergoing oral intubation during general anaesthesia in University Malaya Medical Centre.

研究类型

介入性

注册 (估计的)

398

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Ka Ting Ng, MBChB (Edinburgh)
  • 电话号码:+60379492411
  • 邮箱:katingng1@um.edu.my

学习地点

    • Kuala Lumpur
      • Kuala Lumpur、Kuala Lumpur、马来西亚、59100
        • Universiti Malaya Medical Centre

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults aged 18-65 years.
  • American Society of Anaesthesiologists (ASA 1-2).
  • Scheduled for elective non-airway surgery requiring general anaesthesia with orotracheal intubation of anticipated duration ≥ 90 minutes.
  • Able to understand the patient information sheet (in English or Bahasa Malaysia) and provide written informed consent.

Exclusion Criteria:

  • ASA physical status III-V.
  • Body mass index < 18 or > 40 kg/m².
  • Known hypersensitivity to amide local anaesthetics, including lignocaine.
  • Anticipated difficult airway (Mallampati III-IV, mouth opening < 3 cm, restricted neck extension, thyromental distance < 6 cm).
  • Upper respiratory tract infection within the preceding 2 weeks; chronic cough; pre-existing sore throat or hoarseness.
  • Airway, head-and-neck, dental, or thoracic surgery; surgery requiring transoesophageal echocardiography.
  • History of significant cardiac arrhythmia, second- or third-degree heart block, or hepatic impairment (Child-Pugh B or C).
  • Pregnancy or lactation.
  • Inability to perform self-report outcome assessment owing to cognitive impairment or language barrier.
  • Concurrent systemic lignocaine or anti-arrhythmic class I therapy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
有源比较器:Group L (lignocaine)

IV lignocaine 1.5 mg/kg, calculated on lean body weight (LBW).

安慰剂比较:Group P (placebo)

0.9% normal saline

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of postoperative sore throat (POST)
大体时间:1-hour, 6-hour, 24-hour after surgery

Patient-reported pain/discomfort in throat (yes/no) on standardised question.

1-hour, 6-hour, 24-hour after surgery

次要结果测量

结果测量
措施说明
大体时间
Severity of POST
大体时间:1-hour, 6-hour, 24-hour after surgery

NRS 0-10 (0 = none, 10 = worst imaginable).

1-hour, 6-hour, 24-hour after surgery
Incidence and severity of postoperative cough
大体时间:1-hour, 6-hour, 24-hour after surgery

Observation of cough in post anaesthesia care unit (yes/no); 4-point scale: 0 none, 1 mild (single), 2 moderate (> 1 episode), 3 severe (constant).

1-hour, 6-hour, 24-hour after surgery
Incidence of post-extubation hoarseness
大体时间:1-hour, 6-hour, 24-hour after surgery

Stout's 4-point grading: 0 no hoarseness, 1 mild hoarseness (only noticed by patient), 2 severe hoarseness (noticed by medical personnel), 3 aphonia (total inability to speak)

1-hour, 6-hour, 24-hour after surgery
Patient satisfaction
大体时间:24-hour after surgery

NRS 0-10 (0 = not satisfy, 10 = very satisfy)

24-hour after surgery
Adverse events of intravenous lignocaine
大体时间:During surgery and 1-hour after surgery in post anaesthesia care unit

haemodynamic events (HR < 50 or > 100, MAP < 65 or > 110); seizure, perioral numbness, dizziness, tinnitus.

During surgery and 1-hour after surgery in post anaesthesia care unit

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年11月4日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月13日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Requests for de-identified data from qualified researchers may be considered by the principal investigator on a case-by-case basis, subject to approval by the ethics committee.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅